Werewolf Therapeutics reports clinical trial data for cancer drugs

Werewolf Therapeutics (NASDAQ:HOWL) presented clinical trial data for two cancer drugs at a conference. WTX-124 showed responses in solid tumors, with a 37.5% response rate in lung cancer when combined with pembrolizumab. WTX-330 showed a partial response in gallbladder cancer. The FDA agreed on a Phase 2 dose for WTX-124. Data was current as of mid-2026.

Original reporting
Published Nov 9, 2026, 1:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 1:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$HOWL
Bullish
high confidence
Mentioned
$HOWL
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HOWLBullishMed
01

Why it matters

The disclosed response rates (37.5% in NSCLC combo, 15.8% in melanoma combo) and the recommended Phase 2 dose provide concrete milestones that can be incorporated into valuation models.

02

Market read

First‑time disclosure of early‑stage trial data for a micro‑cap biotech, likely to move the stock and influence sector sentiment.

03

What to watch

Regulatory timeline and potential competition from other checkpoint inhibitor combos could temper upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Werewolf Therapeutics (NASDAQ:HOWL) is a clinical‑stage biotech focused on engineered cytokine therapeutics. The SITC meeting is a key venue for oncology data releases.

Company-level read

Ticker impact

$HOWLBullishHigh confidence
Context

Werewolf Therapeutics presented new Phase 1/1b data for WTX-124 and Phase 1b/2 data for WTX-330 at the SITC meeting, including response rates and a recommended Phase 2 dose.

Expected impact

likely upward pressure as the market prices in the encouraging response rates and lack of vascular leak syndrome.

Evidence & confidence

First disclosure of trial data for a micro‑cap biotech; early efficacy signals are material for valuation and typically trigger price moves.

Market effects

Positive data may boost sentiment toward the broader immuno‑oncology sector and other early‑stage biotech peers.

Limited to U.S. biotech investors; no broader regional effect.

Modest global relevance as the data could influence cross‑border collaborations in cancer immunotherapy.

Counterpoint

Investors may question the small sample size and lack of long‑term survival data, keeping the stock volatile.

Key entities

  • Werewolf Therapeutics Inc.

    Biotech developing WTX-124 and WTX-330 cytokine therapies.

  • Society for Immunotherapy of Cancer (SITC)

    Conference where the data were presented.

Related articles

$HOWLMedAI 8/10

Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

Werewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting – In a Phase 1/1b clinical trial , WTX-124 was administered safely at its recommended Phase 2 dose of 18 mg IV Q2W in the ou

$HOWLHighAI 8/10

Werewolf Therapeutics And Ambros Therapeutics Announce Merger; Secure $150M Financing

Werewolf Therapeutics (HOWL) and Ambros Therapeutics announced an all-stock merger, creating a Nasdaq-listed biotech firm focused on neridronate for CRPS-1. The combined company, trading as AMBX, secured $150M in financing. Neridronate has FDA designations and is in Phase 3 trials, with results expected in 2028. The merger values Ambros at $500M and Werewolf at $47.5M, with a planned Q1 2027 close. HOWL shares surged 1431.19% in pre-market trading.